You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for BAY 293
BAY 293 is a potent KRas/son of sevenless 1 (SOS1) interaction inhibitor (IC50 = 21 nM); active R-enantiomer. Downregulates active RAS in tumor cells. Inhibits RAS-RAF-MEK-ERK pathway. Exhibits synergistic effects with KRASG12C inhibitor ARS-853.
Negative control also available.
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the BAY 293 probe summary on the SGC website.
Compound Libraries for BAY 293
Technical Data for BAY 293
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for BAY 293
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for BAY 293
The following data is based on the product molecular weight 448.59. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.23 mL||11.15 mL||22.29 mL|
|5 mM||0.45 mL||2.23 mL||4.46 mL|
|10 mM||0.22 mL||1.11 mL||2.23 mL|
|50 mM||0.04 mL||0.22 mL||0.45 mL|
References for BAY 293
References are publications that support the biological activity of the product.
Hillig et al (2019) Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc.Natl.Acad.Sci.USA. 116 2551 PMID: 30683722
If you know of a relevant reference for BAY 293, please let us know.
View Related Products by Product Action
Keywords: BAY 293, BAY 293 supplier, BAY293, Potent, KRas/son, of, sevenless, 1, SOS1, interaction, inhibitors, inhibits, Ras, GTPases, 6857, Tocris Bioscience
Citations for BAY 293
Citations are publications that use Tocris products.
Currently there are no citations for BAY 293. Do you know of a great paper that uses BAY 293 from Tocris? Please let us know.
Reviews for BAY 293
There are currently no reviews for this product. Be the first to review BAY 293 and earn rewards!
Have you used BAY 293?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
RAS Oncoproteins Scientific Review
Written by Kirsten L. Bryant, Adrienne D. Cox and Channing J. Der, this review provides a comprehensive overview of RAS protein function and RAS mutations in cancer. Key signaling pathways are highlighted and therapeutic vulnerabilities are explored. This review also includes a detailed section on RAS drug discovery and targeting synthetic lethal interactors of mutant RAS. Compounds available from Tocris are listed.
Cell Cycle & DNA Damage Repair PosterUpdated
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.